NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis $1.64 +0.06 (+3.80%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.57▼$1.6950-Day Range$1.23▼$1.7852-Week Range$0.98▼$2.57Volume9,169 shsAverage Volume169,927 shsMarket Capitalization$45.87 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get NextCure alerts: Email Address NextCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside265.9% Upside$6.00 Price TargetShort InterestHealthy0.40% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment1.11Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.71) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.71 out of 5 starsMedical Sector63rd out of 936 stocksPharmaceutical Preparations Industry19th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNextCure has only been the subject of 2 research reports in the past 90 days.Read more about NextCure's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.40% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 14.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNextCure has received a 71.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for NextCure is -0.79. Previous Next 2.8 News and Social Media Coverage News SentimentNextCure has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NextCure this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by Insiders13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NextCure's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NextCure are expected to grow in the coming year, from ($1.71) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NextCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About NextCure Stock (NASDAQ:NXTC)NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Read More NXTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXTC Stock News HeadlinesJune 20, 2024 | globenewswire.comNextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceMay 30, 2024 | globenewswire.comNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024July 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 29, 2024 | finance.yahoo.comNextCure, Inc. (NXTC)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid FinancialsMay 2, 2024 | investorplace.comNXTC Stock Earnings: NextCure Misses EPS for Q1 2024May 2, 2024 | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsApril 24, 2024 | globenewswire.comNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024July 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 8, 2024 | markets.businessinsider.comPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy RatingApril 8, 2024 | globenewswire.comNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024April 4, 2024 | globenewswire.comNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardApril 2, 2024 | globenewswire.comNextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 27, 2024 | finance.yahoo.comWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?March 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 22, 2024 | markets.businessinsider.comPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy RatingMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)March 21, 2024 | marketwatch.comNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug CandidatesSee More Headlines Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NXTC CUSIPN/A CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees82Year Founded2015Price Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+265.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.29% Return on Assets-47.52% Debt Debt-to-Equity RatioN/A Current Ratio10.70 Quick Ratio10.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.40Miscellaneous Outstanding Shares27,970,000Free Float24,253,000Market Cap$45.87 million OptionableOptionable Beta0.68 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael S. Richman MSBA (Age 63)Co-Founder, CEO, President & Director Comp: $698.39kDr. Solomon Langermann Ph.D. (Age 64)Chief Scientific Officer Comp: $530.32kDr. Han Myint FACP (Age 70)M.D., Chief Medical Officer Comp: $546.66kDr. Lieping Chen M.D. (Age 67)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Mr. Steven P. Cobourn CPA (Age 61)Chief Financial Officer Comp: $313.25kDr. Timothy Mayer Ph.D. (Age 59)Chief Operating Officer Mr. Kevin G. Shaw (Age 49)Senior VP & General Counsel Ms. Stacy RollingerVice President of Human ResourcesMr. Sourav Kundu Ph.D. (Age 63)Senior Vice President of Development & Manufacturing Dr. Sebastien MalovesteSenior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRHookipa PharmaNASDAQ:HOOKParatek PharmaceuticalsNASDAQ:PRTKPuma BiotechnologyNASDAQ:PBYIscPharmaceuticalsNASDAQ:SCPHView All CompetitorsInstitutional OwnershipAssenagon Asset Management S.A.Sold 242,231 shares on 7/18/2024Ownership: 0.660%Affinity Asset Advisors LLCBought 1,359,037 shares on 5/15/2024Ownership: 4.859%Vanguard Group Inc.Bought 83,700 shares on 5/10/2024Ownership: 3.530%View All Institutional Transactions NXTC Stock Analysis - Frequently Asked Questions How have NXTC shares performed this year? NextCure's stock was trading at $1.14 at the beginning of 2024. Since then, NXTC shares have increased by 43.9% and is now trading at $1.64. View the best growth stocks for 2024 here. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) announced its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.16. When did NextCure IPO? NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO. Who are NextCure's major shareholders? Top institutional investors of NextCure include Assenagon Asset Management S.A. (0.66%). View institutional ownership trends. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), Organigram (OGI) and Kadmon (KDMN). This page (NASDAQ:NXTC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.